ArticleInternational journal of molecular sciences2026
MERS-Mpro Predictor: A Machine Learning-Based Tool for Rapid Screening of Potential MERS-CoV Main Protease Inhibitors.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Middle East Respiratory Syndrome coronavirus (MERS-CoV) remains a significant global health concern due to the absence of approved antiviral therapeutics. In this study, we developed a ligand-based machine learning framework to identify potential inhibitors of the MERS-CoV main protease (Mpro) using molecular representations derived from SMILES strings. Multiple classification algorithms, including logistic regression, support vector machines, random forests, and Extreme Gradient Boosting (XGBoost), were systematically evaluated. Model performance was assessed through both internal validation and an external dataset. While several models exhibited strong performance during validation, the Random Forest classifier demonstrated the most robust and consistent generalization, achieving superior predictive performance on the external dataset. To ensure model reliability, a comprehensive validation strategy was implemented, including strict data partitioning to prevent structural overlap, Y-scrambling analysis to eliminate chance correlations, and applicability domain assessment to define the model's reliable prediction space. The final model was deployed as an interactive web-based application, enabling rapid virtual screening of compounds through single or batch SMILES input, and providing activity predictions along with probability scores and selected physicochemical descriptors. Overall, this study presents a reproducible ligand-based approach for supporting the early-stage identification of potential MERS-CoV Mpro inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.